Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BPR0C305, an orally active microtubule-disrupting anticancer agent.
Li WT, Yeh TK, Song JS, Yang YN, Chen TW, Lin CH, Chen CP, Shen CC, Hsieh CC, Lin HL, Chao YS, Chen CT. Li WT, et al. Among authors: lin ch, lin hl. Anticancer Drugs. 2013 Nov;24(10):1047-57. doi: 10.1097/CAD.0000000000000014. Anticancer Drugs. 2013. PMID: 24025560
BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Ho PY, Chen TW, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Hwang DR, Chern JH, Hwang LL, Chang JY, Chao YS, Chen CT. Hu CB, et al. Among authors: lin ch, lin hl. Cancer Sci. 2011 Jan;102(1):182-91. doi: 10.1111/j.1349-7006.2010.01744.x. Epub 2010 Oct 12. Cancer Sci. 2011. PMID: 21040217 Free article.
Putative tumor metastasis-associated genes in human gastric cancer.
Tuan TF, Chung CT, Tsou HH, Chen FW, Lin HL, Lai YK, Lee WS, Chao YS, Hwang LL, Chen CT. Tuan TF, et al. Among authors: lin hl. Int J Oncol. 2012 Sep;41(3):1068-84. doi: 10.3892/ijo.2012.1502. Epub 2012 May 31. Int J Oncol. 2012. PMID: 22664961
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. Among authors: lin hl. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.
712 results